Citations

Showing 10 of 108104 citations.

Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy
Basu, Ananda

Mayo Clinic

ACP Journal Club | January 18, 2022 | Volume: 147 | Issue: 2 | Pages: 47

10.7326/acpjc-2007-147-2-047 | PMID 17764138 Get It

Severe alcoholic hepatitis as precipitant for organ failure and ACLF
Trebicka, Jonel , Arroyo, Vicente , Shah, Vijay H. , Moreau, Richard , Moreau, Richard , Trebicka, Jonel , Louvet, Alexandre , Jalan, Rajiv

Mayo Clinic

Zeitschrift für Gastroenterologie | January 18, 2022 | Volume: 60 | Issue: 01 | Pages: 67-76

10.1055/a-1713-3796 | PMID 35042255 Get It

Abstract Alcoholic hepatitis is the acute deterioration of alcoholic liver disease with rapid onset or worsening of jaundice, which in severe cases, may transition to acute-on-chronic liver failure with extremely high short-term mortality, increasing with the number and severity of hepatic and extra-hepatic organ dysfunction. Diagnosis and treatment are insufficient and challenging, especially due to the complex, multi-factorial and as yet not fully understood pathogenesis. While current management is limited to steroids and best supportive care, debate is ongoing concerning liver transplantation for selected patients, and several novel approaches are under way with mixed results. These drawbacks in disease management together with increasing prevalence in Germany, and generally in Western countries, constitute an unmet need for the healthcare systems. This review tries to summarize the current status of these aspects and provides an overview for pathogenesis, management and potential future treatments.
Association of Area-Level Socioeconomic Deprivation With Hypoglycemic and Hyperglycemic Crises in US Adults With Diabetes
Heien, Herbert C., Sangaralingham, Lindsey R. , Inselman, Jonathan , Shah, Nilay D. , Kurani, Shaheen Shiraz, Inselman, Jonathan W, Kurani, Shaheen , Golden, Sherita Hill , McCoy, Rozalina G.

Mayo Clinic

JAMA Network Open | January 18, 2022 | Volume: 5 | Issue: 1 | Pages: e2143597

10.1001/jamanetworkopen.2021.43597 | PMID 35040969 Get It

From Millstones to Milestones
Pharr, Emily P., Jones, Lyell K , Pharr, Emily P.

Mayo Clinic

Neurology | January 18, 2022 | Volume: 98 | Issue: 9 | Pages: 349-350

10.1212/wnl.0000000000200061 | PMID 35042739 Get It

Artificial intelligence can overcome challenges in brachytherapy treatment planning
Cunha, J. Adam M. , Jia, Xun , Rong, Yi

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 18, 2022 | Volume: 23 | Issue: 1 | Pages: No page available

10.1002/acm2.13504 | PMID 35041263 Get It

Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign
Josephs, Kennedy A., Pham, Nha Trang Thu, Graff‐Radford, Jonathan , Lowe, Val J. , Whitwell, Jennifer L., Machulda, Mary M. , Whitwell, Jennifer

Mayo Clinic

Journal of Alzheimer's Disease | January 18, 2022 | Volume: 86 | Issue: 1 | Pages: 491-498

10.3233/jad-215263 | PMID 35068459 Get It

Background: It has been hypothesized that medial temporal sparing may be related to preserved posterior cingulate metabolism and the cingulate island sign (CIS) on [18F]fluorodeoxyglucose (FDG) PET in posterior cortical atrophy (PCA). Objective: To assess the severity of medial temporal atrophy in PCA and determine whether the presence of a CIS is related to medial temporal sparing. Methods: Fifty-five PCA patients underwent MRI and FDG-PET. The degree and symmetry of medial temporal atrophy on MRI was visually assessed using a five-point scale for both hemispheres. Visual assessments of FDG-PET coded the presence/absence of a CIS and whether the CIS was symmetric or asymmetric. Hippocampal volumes and a quantitative CIS were also measured. Results: Medial temporal atrophy was most commonly mild or moderate, was symmetric in 55% of patients, and when asymmetric was most commonly worse on the right (76%). Older age and worse memory performance were associated with greater medial temporal atrophy. The CIS was observed in 44% of the PCA patients and was asymmetric in 50% of these. The patients with a CIS showed greater medial temporal asymmetry, but did not show lower medial temporal atrophy scores, compared to those without a CIS. Hippocampal volumes were not associated with quantitative CIS. Conclusion: Mild medial temporal atrophy is a common finding in PCA and is associated with memory impairment. However, medial temporal sparing was not related to the presence of a CIS in PCA.
Dependence of Water-equivalent Diameter and Size-specific Dose Estimates on CT Tube Potential
McCollough, Cynthia H. , McCollough, Shannon , Schneider, Justine J. , Moen, Taylor R., Weaver, Jayse , Vrieze, Thomas J., Yu, Lifeng , Leng, Shuai , McCollough, Shannon L , Weaver, Jayse M , McCollough, Cynthia H , Leng, Shuai , Yu, Lifeng

Mayo Clinic

Radiology | January 18, 2022 | Volume: 303 | Issue: 2 | Pages: 404-411

10.1148/radiol.210860 | PMID 35040673 Get It

Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease
Isley, William L.

Mayo Clinic

ACP Journal Club | January 18, 2022 | Volume: 144 | Issue: 2 | Pages: 34

10.7326/acpjc-2006-144-2-034 | PMID 16539349 Get It

Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors
Zhu, Mojun, Costello, Brian A., Yin, Jun, Pettinger, Adam M., Strosberg, Jonathan R., Erlichman, Charles, Hobday, Timothy J., Zhu, Mojun, Costello, Brian A., Yin, Jun, Pettinger, Adam M., Strosberg, Jonathan R., Erlichman, Charles, Hobday, Timothy J.

Mayo Clinic

Pancreas | January 18, 2022 | Volume: 50 | Issue: 10 | Pages: 1435-1439

10.1097/mpa.0000000000001950 | PMID 35041344 Get It

Objectives Systemic therapies for pancreatic neuroendocrine tumors (PNETs) are limited. The combination of bevacizumab and temsirolimus showed significant antitumor activity, but the single-agent activity of bevacizumab was unknown. We conducted a single-arm, phase II trial to evaluate the efficacy of bevacizumab in PNETs. Methods Patients with progressive disease by the Response Evaluation Criteria in Solid Tumors version 1.1 within 7 months of enrollment were eligible for bevacizumab 10 mg/kg every 2 weeks. Adverse events were assessed according to the Common Terminology Criteria for Adverse Events version 3.0. The primary end point was response rate (RR). Results Twenty-four patients were enrolled and followed up for a median duration of 36.1 months. Confirmed RR was 12.5%; 75.0% of patients had stable disease at 6 months. Median progression-free survival was 18.0 months; median overall survival was not reached. Common grade 3 adverse events were hypertension (45.8%) and proteinuria (8.3%). No grade 4 adverse events were observed. Conclusions Bevacizumab demonstrated promising antitumor activity in progressive PNETs comparable to standard targeted therapy. Although this study failed to reject the null hypothesis (RR, 10%), bevacizumab seems a reasonable monotherapy and a potential component of combination therapies given clinical activity and low rates of adverse events.